Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 7/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 7/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21348799 | 0.82 | PDE10A (0.48) | PARP1PDE10ATLR7PDE1BSCN9A | |
| SCHEMBL21348794 | 0.79 | PARP1 (0.41) | PARP1PDE10ATLR7PDE1BBRD4 | |
| SCHEMBL11923730 | 0.71 | PDE10A (0.53) | PARP1PDE10ATLR7BRD4 | |
| SCHEMBL11923724 | 0.70 | PARP1 (0.46) | PARP1PDE10ATLR7 | |
| SCHEMBL30665864 | 0.69 | PDE10A (0.37) | PARP1PDE10ATLR7PDE1BBRD4 | |
| SCHEMBL26654603 | 0.69 | PDE10A (0.37) | PARP1PDE10ATLR7PDE1BBRD4 | |
| SCHEMBL6756278 | 0.68 | TLR7 (0.54) | PARP1PDE10ATLR7 | |
| SCHEMBL17712727 | 0.66 | MEN1 (0.64) | DRD2KCNH2 | |
| SCHEMBL30899879 | 0.66 | ACACB (0.39) | PDE10ATLR7PDE1BBRD4 | |
| SCHEMBL30899880 | 0.66 | ACACB (0.39) | PDE10ATLR7PDE1BBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | LYCERA CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | ROCK1, ROCK2, TNK2 | PARP1 3772/4885PDE10A 165/4885TLR7 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.